Evaxion picks gonorrhea as second target for vaccine candidate

Encouraging pre-clinical results for Evaxion’s EVX-BV2 candidate have led the firm to add a second target indication, gonorrhea.
Lars Staal Wegner, CEO of Evaxion Biotech | Photo: Evaxion Biotech / PR
Lars Staal Wegner, CEO of Evaxion Biotech | Photo: Evaxion Biotech / PR
by andreas lønstrup, translated by catherine brett

Evaxion Biotech has announced that the firm has chosen sexually transmitted disease gonorrhea as the second target of its EVX-B2 vaccine candidate.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading